Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
Selegiline for Treatment of Cannabis Dependence
3 other identifiers
interventional
19
1 country
1
Brief Summary
During the past 15 years, the demand for treatment for marijuana-related problems in the United States has increased nearly twofold. Selegiline is a medication currently used to treat nicotine dependence. The purpose of this study is to evaluate whether selegiline may be useful in treating individuals with marijuana dependence.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2
Started Mar 2005
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 16, 2005
CompletedFirst Posted
Study publicly available on registry
September 22, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2007
CompletedJanuary 12, 2017
September 1, 2016
2.3 years
September 16, 2005
January 11, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Marijuana addiction severity, Week 9
Marijuana withdrawl symptoms, Week 9
Study Arms (2)
1
EXPERIMENTAL2
PLACEBO COMPARATORInterventions
Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
Eligibility Criteria
You may qualify if:
- Meets DSM-IV criteria for current marijuana dependence
- Positive urine toxicology test for marijuana
- Reports current marijuana use
- Weighs at least 100 lbs
- Women of childbearing age will be included provided they agree to use adequate contraception
You may not qualify if:
- Meets dependence or abuse criteria for alcohol
- Meets dependence criteria for illicit substances other than marijuana
- Serious medical disorders (such as unstable angina or liver failure), that may make participation in the trial unsafe
- Pregnant
- Currently diagnosed with a psychotic disorder
- Currently suicidal or pose a homicidal risk
- Currently taking over-the-counter (e.g., pseudoephedrine) or prescription (e.g., methylphenidate) sympathomimetic agents, antidepressant agents (e.g., tricyclic antidepressants, serotonin reuptake inhibitors, bupropion, other monoamine oxidase inhibitors), or meperidine (Demerol)
- Unable to understand English
- Known hypersensitivity to selegiline hydrochloride
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
MRU
New Haven, Connecticut, 06519, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Brent A Moore, Ph.D.
Yale University
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- NIH
Study Record Dates
First Submitted
September 16, 2005
First Posted
September 22, 2005
Study Start
March 1, 2005
Primary Completion
July 1, 2007
Study Completion
July 1, 2007
Last Updated
January 12, 2017
Record last verified: 2016-09